With Britain set to leave the European Union within weeks, Pinder
Sahota at the world's biggest insulin maker Novo Nordisk, and
Sanofi's Hugo Fry have rebuilt operations to withstand the most
turbulent of events.
The two companies told Reuters they had spent millions of pounds,
which they cannot recoup, stockpiling millions of packets of insulin
- used to treat diabetes - inside Britain and building new shipping
and air freight routes.
Their plans, formulated over three years, show the lengths companies
across the continent are having to go to overhaul long-standing
supply chains that may not survive Britain's biggest trade upheaval
in half a century.
"There is nothing comparable to this," Novo Nordisk's UK General
Manager Sahota told Reuters of the Danish company's preparation.
"It's unprecedented from a logistics point of view. We're preparing
for the worst-case scenario, the most extreme."
With two Brexit deadlines already been and gone, Prime Minister
Boris Johnson has vowed to take Britain out of the EU with or
without a deal by Oct. 31 - increasing the chance of a sudden
departure that brings trade tariffs and customs checks with the
continent for the first time in decades.
The government's own planning shows that, in a worst-case scenario,
lorries seeking to enter Europe at the French port of Calais could
face delays of two-and-a-half days, creating supply disruptions that
could last for months.
That poses a real risk for the pharmaceutical industry which imports
37 million packs of drugs from Europe a month. According to the
government, three-quarters come via that route.
While Britain's GSK and AstraZeneca are world leaders in respiratory
and cardiovascular treatments, Britain's insulin is imported.
"In the case of pharmaceuticals, you can't just throw things onto a
boat or a lorry, you have to test and validate these routes into the
country," Fry told Reuters in his office to the west of London,
adding they had backups to their backup plans.
Both Sanofi and Novo Nordisk have reserved space on ferries going
the longer route to eastern English ports to avoid the main
Calais-Dover crossing if needed, and also air freight if required.
"We anticipate that route is going to become congested so what we've
done is open up other routes," said Sahota. "So two other routes
that we've opened up are Denmark to Immingham (in north-east
England) and Netherlands to Immingham."
SKY-HIGH STOCKPILES
Novo Nordisk, Britain's biggest insulin supplier, has tripled its
warehouse capacity to hold 18 weeks' worth of stock - 3.8 million
packs that piled high would stand 12 times the height of the London
Shard skyscraper.
[to top of second column] |
Eli Lilly of the United States and France's Sanofi, the country's
second and third-biggest suppliers, have similar stockpiles.
Frustration is growing that while they dedicate huge resources to
such preparation, they are spending less time on their normal jobs.
"When we're doing this, we're not doing other stuff," Fry said.
"We're not working on projects that will bring our most innovative
products to the market.
"Although we are happy to do it, it is starting to weigh on our
balance sheet, on our logistics, keeping all this additional stock
in the country. It's not an ideal situation."
The companies are confident they will be able to guarantee the
British supply of insulin to the around 1 million diabetes patients
who need it.
But some patients like Georgina from London, who was diagnosed with
Type 1 diabetes more than 30 years ago, have become increasingly
alarmed as the chances have grown of Britain leaving the EU without
a deal to govern their trading relationship.
"For me, I can't tell you how worried I am about that. It's
life-threatening for me," she said, declining to give her last name.
She added that she also worried about older patients she encountered
at clinics.
The British government is organising a regular freight service
reserved just for drugs as part of its preparations alongside
industry for Brexit on Oct. 31.
"We are doing everything we can to help ensure the supply of
medicines and medical products remains uninterrupted, including
insulin," said the department of health and social care.
The two drug companies did not say how much their Brexit
preparations had cost, beyond many millions of pounds. With fixed
contracts with Britain's health service, they cannot raise prices.
Both Fry and Sahota have had to delve into arcane areas of
transport.
As part of their planning, for example, they have had to factor in
how many drivers are needed to avoid breaking legally mandated rest
laws, how long refrigerated lorries can operate in one stretch, and
what happens in the event of fuel shortages.
"We're doing everything we can," said Fry. "I know more about ferry
crossings now than I ever thought I would."
(Editing by Guy Faulconbridge and Pravin Char)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|